Ueyama Hanae, Hinotsu Shiro, Tanaka Shiro, Urushihara Hisashi, Nakamura Masaki, Nakamura Yuji, Kawakami Koji
Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo-ku, Kyoto, 606-8501, Japan.
Drug Saf. 2014 Apr;37(4):259-68. doi: 10.1007/s40264-014-0148-9.
Post-marketing surveillance activities are particularly important for safety issues in children, the elderly, and patients with severe comorbidities since these populations are usually excluded from clinical trials. In addition, using electronic databases for monitoring of safety of marketed products has been of considerable interest.
This study aimed to clarify the advantages and difficulties of the self-controlled case series method relative to cohort studies in pharmacoepidemiological studies in children, using an administrative database, and to explore the impact on results of handling the period eligible for analysis and recurrent events in different ways.
Datasets of only individuals who had the outcome of interest were derived from an anonymized hospital administrative database in Japan from April 2003 through August 2011. We calculated incidence rate ratios (IRRs) and their 95 % confidence intervals (CIs) for the risks of diarrhea, bronchitis, and eczema related to palivizumab treatment in young children. The analysis included 'first diagnosed' events or 'multiple' events during an eligible period. An eligible period was defined in two ways: first-time inpatient periods of more than 3 continuous days (EPA); and a continuous period in cases where the interval between visits was below the 75th percentile of the interval between visits for patients with the same diagnosis (EPB).
We extracted data for 70,771 patients and identified 641 who were exposed to palivizumab. The age-adjusted IRRs for diarrhea, bronchitis, and eczema were 3.0 (95 % CI 1.7-5.4), 10.3 (95 % CI 8.0-13.2), and 16.9 (95 % CI 12-23), respectively, in multiple events and the EPB eligible period. The IRRs varied greatly between the two eligible periods.
This method could be a useful tool in pharmacoepidemiological studies in children. Careful consideration in the handling of inpatient and outpatient periods, including sensitivity analyses, is necessary because this method is a within-individual comparison.
上市后监测活动对于儿童、老年人以及患有严重合并症的患者的安全问题尤为重要,因为这些人群通常被排除在临床试验之外。此外,利用电子数据库监测上市产品的安全性也备受关注。
本研究旨在阐明在儿童药物流行病学研究中,相对于队列研究,使用行政数据库的自控病例系列方法的优势和困难,并探讨以不同方式处理符合分析条件的时间段和复发事件对结果的影响。
仅从2003年4月至2011年8月日本一家匿名医院行政数据库中提取有感兴趣结局的个体数据集。我们计算了幼儿中与帕利珠单抗治疗相关的腹泻、支气管炎和湿疹风险的发病率比(IRR)及其95%置信区间(CI)。分析包括符合条件期间的“首次诊断”事件或“多次”事件。符合条件的时间段有两种定义方式:连续住院超过3天的首次住院时间段(EPA);以及对于同一诊断患者,就诊间隔低于就诊间隔第75百分位数的连续时间段(EPB)。
我们提取了70771名患者的数据,确定了641名接触过帕利珠单抗的患者。在多次事件和符合EPB条件的时间段中,腹泻、支气管炎和湿疹的年龄调整后IRR分别为3.0(95%CI 1.7 - 5.4)、10.3(95%CI 8.0 - 13.2)和16.9(95%CI 12 - 23)。两个符合条件的时间段之间IRR差异很大。
该方法可能是儿童药物流行病学研究中的一种有用工具。由于此方法是个体内比较,因此在处理住院和门诊时间段时,包括敏感性分析,需要仔细考虑。